The global transdermal patch market, valued at $7.8 billion in 2023, is on a trajectory to reach nearly $10.95 billion by 2030, with pain patches leading the charge. This growth is not merely about convenience but addresses critical healthcare challenges, including managing chronic pain in aging populations and providing needle-free medication delivery. Importantly, it presents a safer alternative to traditional opioid use, with the abuse-deterrent opioid segment projected to more than double between 2024 and 2030.
Nutriband Inc. (NASDAQ: NTRB) is at the forefront of this shift with its AVERSA Fentanyl patch, designed to deter abuse through its proprietary AVERSA technology. With potential peak annual US sales of up to $200 million and a revenue-generating subsidiary, Nutriband is reducing dilution risk while advancing towards FDA approval. Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is making strides in pain and ADHD treatments, reporting a 23% year-over-year revenue increase in Q1 2025, supported by a strong product portfolio and shareholder-focused capital allocation.
Assertio Holdings, Inc. (Nasdaq: ASRT) is transitioning into a specialty pharmaceutical company, focusing on high-potential assets and settling legacy legal issues. With Rolvedon and Sympazan outperforming expectations, Assertio is poised for growth. Aquestive Therapeutics, Inc. (Nasdaq: AQST) is advancing innovative drug delivery technologies, with its Anaphylm™ oral sublingual film for severe allergic reactions nearing FDA approval, offering a non-invasive alternative to current treatments.
These companies exemplify the innovative approaches being taken to address the opioid crisis and improve patient care through safer, more effective drug delivery methods. Their progress underscores the potential for significant impact on healthcare, offering hope for safer pain management solutions and highlighting the importance of investment in biopharmaceutical innovation.
